Rohm and Haas president addresses Morgan Stanley Chemicals Conference

President and Chief Operating Officer J. Michael Fitzpatrick told investors today that Rohm and Haas is continuing to bring new, innovative products to market and remains on track to attain its cost reduction goals.

Speaking at a conference in New York City, Fitzpatrick characterized 2001 as a transition year, one in which Rohm and Haas instituted stringent cost reduction programs aimed at improving the company's operating run rate by $200 million upon completion in October 2002.He noted that the company strengthened its business portfolio through the divestiture of its agricultural chemicals business and the decision to exit some smaller, lower-performing businesses. Also, small, bolt-on acquisitions were made to support some of the stronger segments of the portfolio. He noted that the company used the net proceeds from these activities to strengthen the company's balance sheet. The debt-to-capital ratio was reduced from 49 percent at the beginning of 2001, to 42 percent as of December 31st.

Fitzpatrick characterized 2002 as a momentum year for Rohm and Haas. He said that the key markets into which the company sells are showing overall signs of stability, but expects to see overall demand in the first half of 2002 similar to that of the last six months of 2001. Nevertheless, the company continues to report growth for new technologies recently introduced, especially those targeted at the high end of the markets in which they compete. He pointed to next-generation versions of opaque polymers, road-marking paints and new water-based emulsions for more environmentally-friendly paints as examples of success in the global coatings market, and noted growth for adhesive technology aimed at the flexible packaging market, as well as new preservative technology for the personal care market. Newer electronic materials technologies, especially those used for making high-performance semiconductors, also are doing well, relative to the depressed electronics market overall.

He concluded by observing that cost reductions and greater operating efficiencies should allow the company to report improved earnings in 2002, even without a significant increase in external economic demand. Said Fitzpatrick, "Rohm and Haas continues to demonstrate that it is actively managing its way through this part of the economic cycle and bringing innovative technology to market to ensure a good return to its shareholders."

600450 Rohm and Haas president addresses Morgan Stanley Chemicals Conference

See more news about:

Others also read

William A. Wulfsohn, vice president and general manager of Nylon System for Honeywell International, has been named vice president of European coatings for PPG Industries (NYSE:PPG) and managing director of PPG Europe. "Bill will play a vital role in helping our European coatings businesses achieve their full potential," said Michael A.
Apogee Enterprises Inc. reported level sales but an increase in earnings for the third quarter of its fiscal 2003. Bloomington-based Apogee, which makes glass products and services, said the earnings increase was mainly the result of improvements in its architectural glass business.
Bystronic is to take over Armatec Vierhaus GmbH with effect from 1 January 2003. For Bystronic, a global supplier of system solutions for the manufacture of architectural and automotive glass, the takeover of Armatec, which specialises in laminated safety glass and handling systems, ideally complements the Bystronic portfolio.
The butterflies at Melbourne Zoo have gone upmarket with a new accommodation wing featuring Pilkington glass.
Owens-Brockway Glass Container Inc., an indirect wholly-owned subsidiary of Owens-Illinois, Inc., (NYSE: OI) announced today that is has closed on the sale of $175 million principal amount of its 8-3/4% Senior Secured Notes due November 15, 2012.
UCB reached an agreement with Solutia to acquire Solutia's Resins, Additives & Adhesives activity for $500 million, plus a $10 million exclusivity fee.

Add new comment